Can Immunotherapy's hidden toll on daily life be measured?
NCT ID NCT07754409
First seen Aug 10, 2026 · Last updated Sep 03, 2026 · Updated 3 times
Summary
This study follows 75 people with locally advanced non-small cell lung cancer who receive a year of adjuvant immunotherapy after chemoradiotherapy. Researchers will use questionnaires to track changes in quality of life and self-reported health from the start of immunotherapy to 12 months later. The goal is to understand how this newer treatment affects patients' daily well-being, so healthcare teams can better support them during and after therapy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Adjuvant immunotherapy (immune checkpoint inhibitors) after chemoradiotherapy
- What this could lead to
- If successful, this could reveal how adjuvant immunotherapy affects patients' daily lives, guiding better support and care during treatment.
- What could go wrong
- This is a small observational study, so findings may not apply to all patients. It does not test a new treatment, so it won't directly change outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2029
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients cared for at a specialized oncology centre in Västra Götaland, Sweden and at a regional hospital in Jönköping region in Sweden.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with locally advanced non-small lung cancer * cared for at either one of two specialized oncology centres * ≥ 18 years of age * planned for concurrent chemoradiotherapy including ICI for 12 months * performance status 0-2. Exclusion Criteria: * diseases or comorbidities that may have significant impact on the outcome variables * limited understanding of the Swedish language preventing the possibility to give oral and written informed consent.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Non-small cell carcinoma of lung are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Department of Oncology, Sahlgrenska University Hospital
RECRUITINGGothenburg, 405 30, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.